[[{“fid”:”317215″,”view_mode”:”default”,”fields”:{“field_file_image_alt_text[und][0][value]”:””,”field_file_image_title_text[und][0][value]”:””},”type”:”media”,”attributes”:{“height”:187,”width”:300,”style”:”float: right; margin: 10px;”,”class”:”media-element file-default”}}]]Vancive Medical Technologies and CareFusion Corporation announced an exclusive agreement in the United States, Canada and Mexico for the licensing and distribution of Vancive’s BeneHold Chlorhexidine Gluconate (CHG) antimicrobial Adhesive Technology for applications in vascular access. Under the agreement, CareFusion will market Vancive’s unique antimicrobial adhesive technology used with transparent dressings that are ideally suited for protection of catheter insertion sites. The first product received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in September 2012 and will be co-branded under CareFusion’s new ChloraShield brand.

For more information, visit www.vancive.averydennison.com and www.carefusion.com